Inside the research
Revvity, Inc.
RVTY Research profile · latest available data
Price overview
$151.11
▲ +0.43 (+0.3%)
| 52w hi | $151.11 |
|---|---|
| 52w lo | $82.21 |
| Vol | 1.94M |
| As of | 25 Sep 2026 |
The Verdict
Our score +0.30
| Short | +0.38 |
|---|---|
| Medium | +0.40 |
| Long | -0.05 |
computed 2026-09-27
Key fundamentals
Revvity, Inc.
Healthcare · Diagnostics & Research
| Market cap | $16.86B |
|---|---|
| Enterprise value | $19.18B |
| Trailing P/E | 72.30x |
| Forward P/E | 25.64x |
| EV / EBITDA | 21.90x |
| P / S (ttm) | 5.79x |
| Profit margin | 8.2% |
| Return on equity | 3.2% |
| Revenue growth | +1.3% |
| Earnings growth | +1.2% |
| Debt / equity | 46.23 |
Layer Breakdown
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | +0.07 | |
| Sector | +0.08 | |
| Technical | +0.28 | |
| Earnings | +0.00 | |
| Sentiment | +0.00 |
macro × 1.00 · 2026-09-27
Business overview
Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. The company also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray , EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
Risk Metrics
| Beta vs SPX | 1.12 |
|---|---|
| Corr SPX | 0.47 |
| Annual vol | 38.1% |
| Annual ret | +17.5% |
| Sharpe | 0.46 |
| Max DD | -35.6% |
Window: 504 trading days (504 obs)
Analyst Coverage
| Mean PT | $113.64 |
|---|---|
| High / Low | $145.00 / $90.00 |
| Median | $110.00 |
| Analysts | 14 |
| Strong Buy | 1 | |
|---|---|---|
| Buy | 6 | |
| Hold | 9 | |
| Sell | 0 | |
| Strong Sell | 0 |
Recent rating actions
| 2026-05-07 | Barclays | → Equal-Weight |
| 2026-05-06 | TD Cowen | → Buy |
| 2026-05-06 | Stifel | → Hold |
| 2026-05-06 | JP Morgan | → Neutral |
| 2026-05-04 | Baird | → Outperform |
| 2026-04-14 | Goldman Sachs | → Neutral |
Material Events
| Date | Event | 8-K |
|---|---|---|
| 2026-08-04 | Earnings Release, Other Material Event… | read |
| 2026-05-05 | Earnings Release, Other Material Event… | read |
| 2026-05-01 | Bylaws Amendment, Shareholder Vote… | read |
| 2026-02-02 | Earnings Release, Exhibits | read |
| 2026-01-13 | Earnings Release, Reg FD Disclosure | read |
| 2025-10-27 | Earnings Release, Exhibits | read |
| 2025-10-24 | Officer / Director Change | read |
| 2025-07-28 | Earnings Release, Exhibits | read |
| 2025-04-28 | Earnings Release, Exhibits | read |
| 2025-04-25 | Bylaws Amendment, Shareholder Vote… | read |
| 2025-01-31 | Earnings Release, Exhibits | read |
| 2025-01-13 | Earnings Release, Reg FD Disclosure | read |
Flow & Concentration
| Insider 180d net | $0 |
|---|---|
| Insider buys / sells | 0 / 0 |
| Insider bias | Neutral |
| 13F holders | 8 |
| Top-5 share | 98.7% |
| HHI | 3,520 (concentrated) |
Top Holders
| Holder | Value | Shares |
|---|---|---|
| State Street Corp | $483.17M | 4.34M |
| Capital Research / Capital World | $207.44M | 1.86M |
| Citadel Advisors | $165.57M | 1.49M |
| Fidelity / FMR LLC | $51.81M | 465.64K |
| AQR Capital Management | $13.96M | 125.49K |
| Millennium Management | $8.37M | 75.23K |
| Bridgewater Associates | $2.69M | 24.16K |
| T. Rowe Price Group | $615.36K | 5.53M |
As of 2026-06-30
Dividends
| Yield (TTM) | 0.14% |
|---|---|
| $ / share (TTM) | $0.21 |
| 5y CAGR | +0.0% |
Annual dividend per share
| 2021 | $0.28 |
|---|---|
| 2022 | $0.28 |
| 2023 | $0.28 |
| 2024 | $0.28 |
| 2025 | $0.28 |
| 2026 | $0.14 |
SEC Filings
The Long Run
FY 2010–2025 · 16 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $2.86B | +3.5% | |
| Gross profit | $693.19M | +13.2% | |
| Operating income | $300.56M | +4.9% | |
| Net income | $693.09M | +15.0% | |
| Cash from ops | $582.93M | +9.5% |
Indices
Recent Sessions
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Sep 25 | $150.70 | $151.99 | $147.03 | $151.11 | 1.94M |
| Sep 24 | $141.79 | $152.26 | $141.79 | $150.68 | 2.54M |
| Sep 23 | $142.40 | $145.00 | $140.08 | $142.11 | 2.24M |
| Sep 22 | $143.12 | $144.77 | $141.71 | $143.31 | 2.87M |
| Sep 21 | $144.53 | $145.55 | $142.30 | $143.59 | 2.06M |
Understand the score. Research layers are inputs to a model, and the available data has limits.
Read the methodology →